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Abstract 
Rifampicin (RIF) is a major component in fixed dose combination therapy for the 
treatment of tuberculosis. RIF has low solubility and high permeability with high 
dose and hence it is classified as class II drug in Biopharmaceutical 
Classification System (BCS). RIF has poor and variable bioavailability because 
of its poor solubility, acid decomposition and, drug and food interaction. The 
present investigation was aimed to develop RIF loaded porous microspheres as 
a controlled release dosage form. Eudragit based porous microspheres of RIF 
were prepared by emulsion solvent diffusion method. Prepared porous 
microspheres were evaluated for its entrapment efficacy, morphology, thermal 
behavior, crystalline nature, in-vitro drug release and stability in simulated 
gastric fluid. The entrapment efficacy of drug loaded microspheres was found to 
be in the range of 19.04–74.57%. Surface morphology revealed the porous and 
spherical structure of microspheres. Differential scanning calorimetric studies 
confirmed that formulation process altered the crystalline nature of RIF. In vitro 
drug release studies indicated that drug to polymer ratio of 2:1 showed more 
than 85% drug release over the period of 3  h. Stability studies in simulated 
gastric fluid (SGF) indicated that low relative decomposition of 18.5% was 
achieved with high drug to low polymer ratio of 1:4. The results obtained from 
the present investigation concluded that RIF loaded porous microspheres are 
suitable for developing oral controlled release dosage form of RIF that can 
prevent acid decomposition and provide better biopharmaceutical properties. 
Further more the microspheres can be evaluated for preventing the interaction 
with isoniazid, other drugs and foodstuffs.  292  S. B. Bhise, A. B. More, and M. Rajkumar:   
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Introduction 
Tuberculosis (TB) is one of the major infectious diseases worldwide and its incidence is 
increasing particularly in association with AIDS pandemic [1]. The four major drugs 
rifampicin (RIF), isoniazid (INH), pyrazinamide (Z) and ethambutol (E) are used widely for 
the treatment of TB [2]. Among these, INH, Z and E belong to the class I (highly 
soluble/highly permeable) of biopharmaceutical classification system whereas RIF is a 
class II drug (low soluble/highly permeable), which has high permeability and low solubility 
[3]. Due to the low solubility, RIF (solubility 2.5 mg/ml, log p 1.086, pKa 4.96±0.7) has poor 
bioavailability in both fixed and single dose formulations [4]. The reason for low 
bioavailability of RIF are changes in the crystalline nature, interaction with excipients, 
degradation in gastro-intestinal tract, variability in absorption and metabolism, its pH 
dependent solubility, etc. [5,  6]. Bioavailability problem of RIF is cause for the poor 
therapeutic outcomes including failure of therapy and drug resistance. Chemotherapy of 
TB is complicated by the need of multi-drug regimens given over long periods, patient non-
compliance and the development of multi-drug resistant strains (MDR) [4]. Poor patient 
compliance is another single most common reason for failure of TB therapy [7]. 
Development of carrier delivery systems that release drugs in a sustained manner at 
therapeutic concentration over a period of time can ensure patient compliance in terms of 
reducing dosing frequency, and may also minimize the risk of emergence of drug resistant 
mutants and potential toxicity [8,  9]. Various carrier systems such as liposomes and 
microspheres have been developed for the sustained delivery of anti tubercular drugs in 
mice with better chemotherapeutic efficacy [10, 11]. However, these formulations have to 
be injected either subcutaneous or intravenous route, which in general is not acceptable. 
Hence, there is a continuous need for development of an oral drug delivery system that is 
convenient for patients. Due to the low solubility, acid decomposition and absorption 
window (RIF has better absorption in stomach due to acidic pH), only few attempts are 
made to develop the oral controlled release formulations for RIF [12]. The present 
investigation is aimed to develop the controlled release porous microspheres of RIF that 
can prevent not only acid decomposition but also controlled release profile of RIF for 
prolonged period of time.  
Results and Discussion 
Preparation of microspheres 
Porous microspheres were prepared by emulsion solvent diffusion method. Various 
amounts of RIF ranging from 0.1 g to 1.0 g were used for preparation of microspheres. 
Drug content of above 0.3 g was given poor spherical structure and hence it was not 
selected for further optimization. Operation temperature ranging from 30–50°C was 
evaluated during the formulation development. At 30 °C, diffusion rate of ethanol was 
found to be more than that of evaporation of dichloromethane and hence it was resulted 
with a sticky mass and formation of microspheres with poor spherical shape. In contrast to 
that at high temperature (of 50°C), evaporation of DCM was faster than the diffusion of 
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that 40°C found to be the optimal operation temperature for formation of porous 
microspheres. Concentration of Eudragit was an important parameter, which determined 
the stability of microspheres during formulation. Drug to polymer ratio ranging from 1:1 to 
1:4 provided stable and porous microspheres.  
Entrapment efficacy 
Entrapment efficacy of drug-loaded microspheres was found to be in the range of 19.04–
74.57% (table 1). Entrapment efficacy was dependent on the composition of drug as well 
as Eudragit. Low content of Eudragit and high composition of drug in formulation resulted 
with low entrapment of drug in microsphere formulations. Drug to Eudragit ratio of 1:4 
yielded maximum entrapment efficacy of 74.57 %, whereas minimum entrapment efficacy 
of 19.04% was observed with 3:1 ratio of drug to Eudragit. However, RIF being a low 
solubility drug with high dose required low concentration of polymer and/or excipients in 
dosage form for better formulation development. Further research is required to improve 
the biopharmaceutical properties of RIF using porous microspheres as a carrier. 
Scanning Electron Microscopy 
The results obtained from SEM studies confirmed the porous and spherical structure of 
microspheres (Fig. 1). Moreover, morphology of microspheres revealed that degree of 
porosity of microspheres were dependent on the composition of Eudragit present in the 
microspheres. High content of Eudragit lead to loss of porosity. There was no pores 
appeared in microspheres with above 500 mg of Eudragit in formulation, whereas less 
than 50 mg content of Eudragit resulted in loss of spherical structure and mechanical 
strength. The effect of Eudragit on porosity is illustrated in Fig 2. The research is aimed to 
develop the porous microspheres, which can control the drug release up to 3 h and hence 
it can prevent the acid decomposition and re-crystallization of RIF in stomach. The results 
obtained from SAM 3 batch resulted in optimal porosity and good spherical structure. 
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Fig. 2.   Effect of Eudragit on porosity of microspheres (left: drug to polymer ratio of 1:4; 
right: drug to polymer ratio of 1:3) 
Differential Scanning calorimetry 
RIF exhibits in two polymorphic forms, i.e. form I and form II [13]. It also exists as hydrates 
and various solvates, which were eventually converted into amorphous form at room 
temperature or after dissolvation [14]. RIF form II, which is metastable, melts at 189°C and 
recyrstallize as a form I at 204 °C. RIF form I has lower chemical stability at higher 
temperature and hence it decompose before melting at 258 °C. Amorphous RIF shows 
exothermic peak, which started at 196 °C, which indicated the crystallization of form I and 
subsequent peak at 258 °C represented the decomposition of RIF form I. DSC 
thermogram of RIF, GSM and Eudragit are shown in Fig 3. DSC thermogram of pure RIF 
showed endothermic peak at 194.03 °C, which represented the melting of form II and 
subsequently exothermic peak at 205.62 °C revealed the crystallization of form I. 
Endothermic peak at 236.07 °C revealed the decomposition form I. Thermal behavior of 
RIF obtained from DSC data confirmed that RIF used in present study exists in form II. 
DSC thermogram of RIF microspheres exhibited small endothermic at 246.29 °C, which 
represented the form I and, confirmed the phase transition (form II to form I) of RIF during 
formulation development. Small exothermic peak intensity of form I from DSC thermogram 
of RIF microspheres indicated that the major portion of RIF in microspheres exists in 
amorphous form. Solid-state stability of RIF is the major problem for poor bioavailability of 
RIF in dosage forms. The study revealed that emulsion diffusion method for preparation of 
RIF microspheres altered the crystalline nature of RIF. Solubility and dissolution studies in 
reported literatures revealed that there was no statistically significant difference in solubility 
and dissolution between two forms of RIF. Moreover, form I is also present in commercial 
dosage form and hence there was no impact of change in polymorphic form during 
formulation development on solubility and dissolution. However, chemical stability of RIF in 
dosage form is an important critical issue, which can affect the biopharmaceutical quality 
of dosage form. Emulsion solvent diffusion method for preparation of RIF microspheres 
was found to be ideal and no impact of process on chemical stability of RIF.  Formulation  and In Vitro Evaluation of Rifampicin Loaded Porous Microspheres  295 
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Fig. 3.   DSC thermogram of RIF, Polymer, physical mixture and microsphere A. GMS ; 
B. Eudragit ; C. Physical mixture ; D. SAM4 microspheres ; E. RIF 
Powder X ray diffraction 
PXRD pattern of RIF, excipients and microspheres formulation are illustrated in Fig 4. The 
peaks at 2 Θ of 9.86 and 2 Θ of 11.84 obtained from RIF confirmed that form II crystals of 
RIF. The hundred percent intensity at 2 Θ of 11.84 confirmed that the presence of form II 
crystals in pure drug. The absence of peak at 2 Θ of 13.65 and 14.95 indicated that the 
RIF form I crystals were absent in the pure drug [15]. However, there was no attempt 
made to quantify the form II present in the RIF. PXRD pattern of microspheres revealed 
the very weak peak intensity at 2 Θ of 13.17 and 15.12 and confirmed that the phase 
transition of form II to form I during the formulation development. This result also revealed 
the major portion of drug exists in the amorphous form. The results obtained from PXRD 
studies were further confirmed by DSC thermogram.  296  S. B. Bhise, A. B. More, and M. Rajkumar:   
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Fig. 4.   Powder X ray diffractogram of RIF, Polymer and microsphere A. GMS ; B. 
Eudragit ; C. RIF; D. SAM4 microspheres 
In vitro dissolution  
In vitro dissolution studies were performed in phosphate buffer 6.8 as a dissolution media 
in order to avoid acid decomposition of RIF in presence of HCl. The rate and extent of 
decomposition of RIF in HCl may affect the quantification of release kinetics of RIF in 
dissolution medium. Microspheres containing 50 mg equivalent of RIF were subjected to 
this study to maintain the sink condition throughout the study. Dissolution studies were 
carried out over the period of 3 h, which mimic the gastric emptying time. The results 
obtained from dissolution studies are graphically represented in fig 5. All the prepared 
microspheres showed controlled release profile. T50% for all the formulation were found to 
be less than 3 h. Drug to Eudragit ratio of 2:1 provided more than 85% release within 3 h. 
The low release profile of 66.85 % was achieved with formulation containing drug to 
Eudragit ratio of 1: 4. High drug to low Eudragit ratio contained microspheres showed burst 
release rather than controlled release profile. Drug to Eudragit ratio of 4:1 to 2: 1 contained  Formulation  and In Vitro Evaluation of Rifampicin Loaded Porous Microspheres  297 
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microspheres has showed immediate release rather than controlled release profile. The in 
vitro drug dissolution studies revealed that high drug to low Eudragit ratio contained 
microspheres can be used to prepare immediate release formulations, whereas low drug 
to high Eudragit ratio containing microspheres could be used to prepare modified release 
dosage form of RIF for improving biopharmaceutical characteristics of RIF.  
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Fig. 5.   Dissolution profile of RIF porous microspheres 
Stability of RIF in SGF 
The purpose of current research work was not only to control the release profile of RIF, but 
also improve the stability of RIF in presence of gastric fluid. In order to find out the stability 
of RIF in stomach, SGF without pepsin [16] was used as a medium for determination of 
relative decomposition of RIF over the period of 3  h. Decomposition of RIF in micro-
spheres was less than that of pure drug (Table 1). The low relative decomposition of 18.5 
% was achieved with low drug to high polymer ratio of 1:4. Moreover, drug decomposition 
in microspheres was dependent on the composition of microspheres. Low drug with high 
Eudragit polymer concentration showed maximum stability of RIF in SGF. Maximum 
relative decomposition of 34.3 % was obtained from drug to polymer ratio of 1:1 and 4:3. 
Stability studies of RIF revealed that microspheres reduced the drug decomposition and 
hence improved the stability of drug in stomach.  
Conclusion 
From the present research work, it can be concluded that the formulation of RIF 
microspheres is a novel approach to improve the stability of RIF and also control the 
release profile of the drug up to 3 h. Emulsion solvent diffusion method was found to be 
effective for preparation spherical and porous microspheres. Drug to Eudragit ratio of 1:1 
to 1:4 has provided not only spherical porous microspheres but also improved stability and 298  S. B. Bhise, A. B. More, and M. Rajkumar:   
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delay rate of drug release. The stability of RIF in in-vitro environments (during formulation 
and in SGF) was achieved with RIF porous microspheres. DSC studies confirmed that the 
major portion of drug was in amorphous form. However, small trace of form I found in DSC 
thermogram demonstrated the phase transition (form II to form I) of RIF during 
microspheres formation. The present study was aimed to develop the RIF microspheres 
that can prevent decomposition of RIF in presence of gastric fluid. However, these 
formulations could be a part of Fixed Dose Combination, which can prevent the interaction 
between RIF and INH. Further in vitro and in vivo studies are required to explore the 
clinical applicability of RIF microspheres particularly in presence of INH.  
Experimental  
Materials 
RIF was gifted from Lupin Research Park, Pune. Glyceryl monostearate was purchased 
from Loba chemi, Mumbai. Eudragit RLPO was gifted by Alembic Ltd., Baroda. Ethanol AR 
and Dichloromethane (HPLC grade) were purchased from Changshu Yangyuan chemical, 
China and Loba Chemie, Mumbai, India, respectively. All other chemicals used were of 
analytical grade or HPLC grade.  
Methods  
HPLC Analysis of RIF 
The HPLC system consisted of PU – 2080 plus intelligent system pump, a sampler with 
20μl loop, a UV detector UV– 2075 plus intelligent set at 254 nm and an interface LC-Net 
II/ADC, all from Jasco (Tokyo, Japan). Samples from dissolution and stability experiments 
were analyzed by a reverse-phase HPLC assay [17]. Detection of RIF was accomplished 
by ultraviolet absorption (254 nm). The reverse-phase column was a Whatman® C18-RP, 
4.6mm×250mm column packed with 5 µ paticles. The mobile phase consisted of 
phosphate buffer (0.5mM): acetonitrile (65:35). The flow rate was 1 ml/min and the 
injection volume was 20 µl. The retention time of RIF was 8 min. Quantification was done 
by use of external standards. The calibration curve was linear in the range 1.5 –100 µg/ml. 
Inter-day precision of the HPLC analysis was estimated by calculating the standard 
deviation of measurements of the external standards on separate days. The coefficient of 
variation was then calculated by dividing the standard deviation of the measurements with 
the mean value. Calculations were made on the highest and lowest concentration of 
external standards used in the HPLC analysis.  
Preparation of microspheres 
Porous microspheres were prepared by the emulsion solvent diffusion method established 
by Kawashima [18] as follows: a drug (0.1–0.3 g), Eudragit® RLPO (0.1–0.4  g) and 
monostearin (GMS) (50 mg) were dissolved or dispersed in a mixture of dichloromethane 
(8 ml) and ethanol (2 ml) at room temperature. The resulting solution was poured into an 
aqueous solution of polyvinyl alcohol (0.25w/v%, 200 ml) at 30, 40 and 50°C. The resultant 
emulsion was stirred at 500 rpm employing a propeller type agitator for 1 h. Subsequently; 
the resulting microspheres were collected and dried overnight at 40°C. Composition of 
optimized formulations is listed in table 1.  
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Tab. 1.   Composition and Pharmaceutical characterization of RIF porous microspheres 
Composition in mg Batch 
Code  RIF EUD**  GMS
T 50%
(min) 
% EE ± SD* % RD ± SD* 
SAM 1  100  100  50    30  56.12 ± 1.34 34.5 ± 3.7 
SAM 2  100  200  50    90  63.99 ± 1.80 31.3 ± 2.9 
SAM 3  100  300  50    60  67.43 ± 3.08 23.3 ± 5.5 
SAM 4  100  400  50  120  74.57 ± 1.15 18.5 ± 1.8 
SAM 5  200  100  50    30  35.72 ± 2.01 45.9 ± 6.0 
SAM 6  200  200  50    60  41.40 ± 2.88 29.5 ± 1.4 
SAM 7  200  300  50    60  49.68 ± 1.96 25.0 ± 2.9 
SAM 8  200  400  50    30  60.61 ± 0.75 25.7 ± 4.0 
SAM 9  300  100  50    30  19.04 ± 3.12 34.3 ± 5.6 
SAM 10  300  200  50    30  23.83 ± 1.26 31.4 ± 3.4 
SAM 11  300  300  50    60  42.77 ± 2.14 16.8 ± 1.9 
SAM 12  300  400  50  900  58.29 ± 2.76 11.4 ± 3.7 
* standard deviation (n=3), ** Eudragit 
 
Pharmaceutical Characterization of porous microspheres 
Encapsulation Efficacy 
The RIF content in the microspheres was determined by pulverizing the RIF-loaded 
microspheres (10 mg) followed by immersing them in 100 ml methanol with agitating at 
room temperature for 10 min. After filtration through a 0.45 μm membrane filter (Millipore), 
the drug concentration was determined HPLC method. All samples were analyzed in 
triplicate and the encapsulation efficiency (EE) was calculated according to the following 
equation: 
100 % ⋅ =
WT
WA
Efficacy ion Encapsulat  
WA: actual drug content;  
WT: theoretical drug content. 
Scanning Electron Microscopy 
The surface topography of the microparticles was examined using optical microcopy and 
scanning electron microscope (Jeol, JSM-5200, Japan, 15 KV). Samples were coated with 
gold film under vacuum using a sputter coater (SPI Sputter™ Coating Unit, SPI Supplies, 
Division of Structure Probe, Inc., PA, USA) and then investigated.  
DSC analysis 
Differential scanning calorimetric (DSC) analyses of the RIF and microspheres were 
carried out by using differential scanning calorimeter equipped with computer analyzer 
(Shimadzu TA–60 differential scanning calorimeter, Shimadzu Corporation, Kyoto, Japan). 
Samples (of 3–7 mg) were heated under nitrogen atmosphere on an aluminum pan at a 
heating rate of 10 °C/min over the temperature range of 50–300 °C. 300  S. B. Bhise, A. B. More, and M. Rajkumar:   
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Powder X- ray diffraction studies 
Powder X-ray diffraction (PXRD) patterns were traced employing X-ray diffractometer 
(Philips PW 1729, Analytical XRD, Holland) for the samples using Ni filtered CuK(α) 
radiation (intensity ratio(α1/  α2): 0.500), a voltage of 40 KV, a current of 30 mA and 
receiving slit of 0.2 inches. The samples were analyzed over 2Θ range of 5.010-39.990
o 
with scanning step size of 0.020
 o (2Θ) and scan step time of one second.  
In Vitro drug dissolution studies  
The drug release rate from porous floating microspheres was determined using USP XXIII 
basket type dissolution apparatus (Lab India Disso 2000, Lab India Ltd., Mumbai). A 
weighed amount of porous microspheres equivalent to 50 mg drug was filled into a 
capsule (# 3) and placed in the basket. Phosphate buffer pH 6.8 was used as the 
dissolution medium and maintained at 37 ± °C at a rotation speed of 100 rpm. Perfect sink 
conditions prevailed during the drug release studies. Five ml sample was withdrawn at 
each 15 min, 30 min, 60 min, 90 min, 120 min, 150 min and 180 min interval, passed 
through a 0.45 μm membrane filter (Millipore), and analyzed by HPLC method to 
determine the concentration of drug present in the dissolution medium. The initial volume 
of the dissolution fluid was maintained by adding 5 ml of fresh dissolution fluid after each 
withdrawal. All experiments were conducted in triplicate. 
Stability of Rifampicin in simulated gastric fluids 
Stability of RIF in microspheres was monitored for 3 h using simulated gastrointestinal fluid 
(without pepsin) as solvent. In brief, formulation contained 10 mg equivalent of RIF were 
dispersed in 100 ml of SGF (S) and incubated in digital shaker with 100 rpm at 37 ºC for 3 
h (Digital incubator shaker, Samruth Electronics, New Delhi). The resultant solution and/or 
suspensions were filtered through 0.2 filters and analyzed by HPLC for its stability. The 
total area of detector response other than RIF was considered as extent of decomposition. 
Percentage relative decomposition (%RD) was calculated using pure RIF as a standard.  
100 % ⋅ =
p
F
TPOR
TPOR
RD  
TPORF: Total area of peak other than RIF peak in formulation 
TPORp: Total area of peak other than RIF peak in Pure drug 
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